3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1
1
Status
Completed
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
CNS
2
Endocrine
1
Conditions
Keratosis, Actinic
22
Brain Neoplasms
10
Glioma
7
Glioblastoma
7
Carcinoma, Basal Cell
4
Precancerous Conditions
2
Mycosis Fungoides
2
Mouth Neoplasms
2
Meningioma
2
Lymphoma, T-Cell, Cutaneous
2
Gliosarcoma
2
Basal Cell Nevus Syndrome
2
Urinary Bladder Neoplasms
1
Squamous Intraepithelial Lesions
1
Skull Base Neoplasms
1
Skin Neoplasms
1
Sezary Syndrome
1
Pituitary Neoplasms
1
Oropharyngeal Neoplasms
1
Oligodendroglioma
1
Nonmelanoma Skin Cancers
1
Neurofibromatoses
1
Neoplasms
1
Nasopharyngeal Neoplasms
1
Lymphoma
1
Leukoplakia
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Laryngeal Neoplasms
1
Hypopharyngeal Neoplasms
1
Interventions
Hydroxyurea
4
aldesleukin
3
Magnetic Resonance Spectroscopy
3
Imatinib Mesylate
3
Everolimus
3
Temozolomide
2
Surveys and Questionnaires
2
Surgical Procedures, Operative
2
Radiotherapy, Intensity-Modulated
2
Radiotherapy, Conformal
2
Psychiatric Rehabilitation
2
Proton Therapy
2
Paclitaxel
2
Laser Speckle Contrast Imaging
2
Filgrastim
2
Donepezil
2
Cyclophosphamide
2
Carmustine
2
Bortezomib
2
Bevacizumab
2
Aminolevulinic Acid
2
90Y-octreotide, DOTA-Tyr(3)-
2
vistusertib
1
vatalanib
1
trametinib
1
tozuleristide
1
temsirolimus
1
sonidegib
1
sargramostim
1
ribociclib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Completed
×
Meningioma
×
Aminolevulinic Acid
×
Clear all
NCT04305470
2026-05-18
MEN-301
NX Development Corp
Phase 3
Completed
108 enrolled
12 charts
NCT00870779
2019-06-14
FGR
Dartmouth-Hitchcock Medical Center
Phase 1
Completed
105 enrolled